Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Overweight on AGCO, Lowers Price Target to $156

Morgan Stanley analyst Courtney Yakavonis maintains AGCO (NYSE:AGCO) with a Overweight and lowers the price target from $170 to $156.

byBenzinga Newsdesk

October 13, 2021

1 minute read

Morgan Stanley analyst Courtney Yakavonis maintains AGCO (NYSE:AGCO) with a Overweight and lowers the price target from $170 to $156.

Telsey Advisory Group Maintains Market Perform on Gap, Lowers Price Target to $33

By Benzinga Newsdesk

Today, 3:19 AM

Telsey Advisory Group analyst Dana Telsey maintains Gap (NYSE:GPS) with a Market Perform and lowers the price target from $38 to $33.

GPS

JonesTrading Initiates Coverage On Dare Bioscience with Buy Rating, Announces Price Target of $6

By Benzinga Newsdesk

Today, 3:19 AM

JonesTrading analyst Catherine Novack initiates coverage on Dare Bioscience (NASDAQ:DARE) with a Buy rating and announces Price Target of $6.

DARE

B of A Securities Upgrades Kymera Therapeutics to Buy, Raises Price Target to $80

By Benzinga Newsdesk

Today, 3:19 AM

B of A Securities analyst Geoff Meacham upgrades Kymera Therapeutics (NASDAQ:KYMR) from Neutral to Buy and raises the price target from $65 to $80.

KYMR

Wall Street Crime And Punishment: Ivan Boesky Gives Greed A Bad Name

By Phil Hall

Today, 3:19 AM

Does crime pay? Wall Street Crime and Punishment is a weekly series by Benzinga's Phil Hall chronicling the bankers, brokers and financial ne’er-do-wells whose ambition and greed take them in the wrong direction.

CVX

Morgan Stanley Maintains Overweight on AGCO, Lowers Price Target to $156

Related Posts

Telsey Advisory Group Maintains Market Perform on Gap, Lowers Price Target to $33

JonesTrading Initiates Coverage On Dare Bioscience with Buy Rating, Announces Price Target of $6

B of A Securities Upgrades Kymera Therapeutics to Buy, Raises Price Target to $80

Wall Street Crime And Punishment: Ivan Boesky Gives Greed A Bad Name